Exacerbation of panic disorder with rifampin therapy in a patient receiving citalopram

Pharmacotherapy

Volumn 25, Issue 3, 2005, Pages 435-437

  Kukoyi, Oladipo ^a   Argo, Tami R ^b   Carnahan, Ryan M ^c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Citalopram; Enzyme induction; Panic disorder; Rifampin; Selective serotonin reuptake inhibitor; SSRI

Indexed keywords

AMFEBUTAMONE; ANALGESIC AGENT; CITALOPRAM; CLINDAMYCIN; CLONAZEPAM; COTRIMOXAZOLE; CYTOCHROME P450 3A4; ESCITALOPRAM; LORAZEPAM; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; VANCOMYCIN;

ADULT; ANXIETY DISORDER; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; ENZYME INDUCTION; HUMAN; MALE; OSTEOMYELITIS; PANIC; WELLBEING;

ANTI-BACTERIAL AGENTS; CITALOPRAM; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ANTAGONISM; ENZYME INDUCTION; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; RIFAMPIN; SEROTONIN UPTAKE INHIBITORS; STAPHYLOCOCCAL INFECTIONS;

EID: 14544276331     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.3.435.61591     Document Type: Article

References (14)

1. Weissman MM, Bland RC, Canino GJ, et al. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 1997;54(4):305-9.
2. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on panic disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 1998; 59(Suppl 8):47-54.
3. Vesely JJ, Pien FD, Pien BC. Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 1998;18(2): 345-57.
4. Swanberg L, Tuazon CU. Rifampin in the treatment of serious staphylococcal infections. Am J Med Sci 1984;287(3):49-54.
5. Finch CK, Chrisman CR, Baciewicz AM, et al. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162:985-92.
6. Markowitz JS, DeVane CL. Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline. J Clin Psychopharmacol 2000;20(1): 109-10.
7. Forest Pharmaceuticals, Inc. Celexa (citalopram hydrobromide) package insert. St. Louis, MO; 2002.
8. Lake BG, Ball SE, Renwick AB, et al. Induction of CYP3A isoforms in cultured precision-cut human liver slices. Xenobiotica 1997;27(11):1165-73.
9. Li AP, Jurima-Romet M. Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin. Cell Biol Toxicol 1997;13:365-74.
10. Hyttel J. Citalopram: pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-95.
11. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997; 280(2):927-33.
12. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. CDER new and generic drug approvals: 1998-2004, application 20822, clinical pharmacology and biopharmaceutics review. Available from www.fda.gov/cder/approval/index.htm. Assessed October 1, 2003.
13. Scheutz EG, Schinkel AH, Relling MV, et al. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A 1996;93(9):4001-5.
14. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97(7):3473-8.